These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 32353509)
1. Comprehensive analysis of cardiac function, blood biomarkers and histopathology for milrinone-induced cardiotoxicity in cynomolgus monkeys. Chiba K; Ishizaka T; Yoshimatsu Y; Mikamoto K; Maeda Y; Iguchi T; Shirai M; Yamaguchi T; Goto K; Sakurai K; Tamai S; Kataoka H; Hasegawa M; Mori K J Pharmacol Toxicol Methods; 2020; 103():106870. PubMed ID: 32353509 [TBL] [Abstract][Full Text] [Related]
2. Promising approach for the preclinical assessment of cardiac risks using left ventricular pressure-volume loop analyses in anesthetized monkeys. Ishizaka T; Yoshimatsu Y; Maeda Y; Takasaki W; Chiba K; Mori K J Pharmacol Toxicol Methods; 2017; 84():1-10. PubMed ID: 27756610 [TBL] [Abstract][Full Text] [Related]
3. Effect of milrinone on echocardiographic parameters after single dose in Beagle dogs and relationship with drug-induced cardiotoxicity. Hanton G; Gautier M; Bonnet P; Herbet A Toxicol Lett; 2005 Feb; 155(2):307-17. PubMed ID: 15603926 [TBL] [Abstract][Full Text] [Related]
4. Assessment of Cardiac Troponin I Responses in Nonhuman Primates during Restraint, Blood Collection, and Dosing in Preclinical Safety Studies. Reagan WJ; Barnes R; Harris P; Summers S; Lopes S; Stubbs M; Blackwell D; Steidl-Nichols J Toxicol Pathol; 2017 Feb; 45(2):335-343. PubMed ID: 27543323 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of Circulating microRNA Specific to the Liver, Heart, and Skeletal Muscle of Cynomolgus Monkeys. Iguchi T; Niino N; Tamai S; Sakurai K; Mori K Int J Toxicol; 2017; 36(3):220-228. PubMed ID: 28460582 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. Cone J; Wang S; Tandon N; Fong M; Sun B; Sakurai K; Yoshitake M; Kambayashi J; Liu Y J Cardiovasc Pharmacol; 1999 Oct; 34(4):497-504. PubMed ID: 10511123 [TBL] [Abstract][Full Text] [Related]
7. Diminished responsiveness to dobutamine as an inotrope in mice with cecal ligation and puncture-induced sepsis: attribution to phosphodiesterase 4 upregulation. Sakai M; Suzuki T; Tomita K; Yamashita S; Palikhe S; Hattori K; Yoshimura N; Matsuda N; Hattori Y Am J Physiol Heart Circ Physiol; 2017 Jun; 312(6):H1224-H1237. PubMed ID: 28455289 [TBL] [Abstract][Full Text] [Related]
8. Effects of milrinone on left ventricular end-systolic pressure-volume relationship of rat hearts in situ. Kishi T; Nakahashi K; Ito H; Taniguchi S; Takaki M Clin Exp Pharmacol Physiol; 2001 Sep; 28(9):737-42. PubMed ID: 11553033 [TBL] [Abstract][Full Text] [Related]
9. Plasma miR-208 as a useful biomarker for drug-induced cardiotoxicity in rats. Nishimura Y; Kondo C; Morikawa Y; Tonomura Y; Torii M; Yamate J; Uehara T J Appl Toxicol; 2015 Feb; 35(2):173-80. PubMed ID: 25092230 [TBL] [Abstract][Full Text] [Related]
10. Longitudinal studies of cardiac troponin I concentrations in serum from male cynomolgus monkeys: resting values and effects of oral and intravenous dosing on biologic variability. Schultze AE; Anderson JM; Kern TG; Justus RW; Lee HY; Zieske LR; Goodson RJ; Florey SH Vet Clin Pathol; 2015 Sep; 44(3):465-71. PubMed ID: 26175009 [TBL] [Abstract][Full Text] [Related]
12. Pharmacology of the bipyridines: amrinone and milrinone. Alousi AA; Johnson DC Circulation; 1986 Mar; 73(3 Pt 2):III10-24. PubMed ID: 2417744 [TBL] [Abstract][Full Text] [Related]
14. [In vivo integrated safety assessment of the cardiovascular system in drug development]. Chiba K Nihon Yakurigaku Zasshi; 2022; 157(1):47-52. PubMed ID: 34980813 [TBL] [Abstract][Full Text] [Related]
15. Effects of milrinone on left ventricular cardiac function during cooling in an intact animal model. Tveita T; Sieck GC Cryobiology; 2012 Aug; 65(1):27-32. PubMed ID: 22465655 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure. Sato N; Asai K; Okumura S; Takagi G; Shannon RP; Fujita-Yamaguchi Y; Ishikawa Y; Vatner SF; Vatner DE Am J Physiol; 1999 May; 276(5):H1699-705. PubMed ID: 10330256 [TBL] [Abstract][Full Text] [Related]
17. Beneficial hemodynamic effects of two weeks' milrinone treatment in conscious rats with heart failure. Schoemaker RG; Debets JJ; Struyker-Boudier HA; Smits JF Eur J Pharmacol; 1990 Jul; 182(3):527-35. PubMed ID: 2226621 [TBL] [Abstract][Full Text] [Related]
18. Treating metabolic impairment and myocardial stunning with phosphodiesterase inhibitor type III, milrinone, administered prior to coronary artery occlusion in the presence of calcium channel blockade in pigs. Sidi A; Muehlschlegel JD; Kirby DS; Lobato EB Ann Card Anaesth; 2007 Jan; 10(1):34-41. PubMed ID: 17455406 [TBL] [Abstract][Full Text] [Related]
19. Myocardial mononuclear cell infiltrates are not associated with increased serum cardiac troponin I in cynomolgus monkeys. Dunn ME; Coluccio D; Zabka TS; Gopalakrishnan G; Hirkaler G; Geng W; Nicklaus R; Lipshultz SE; Doessegger L; Saladino BH; Singer T; Mikaelian I Toxicol Pathol; 2012 Jun; 40(4):647-50. PubMed ID: 22298795 [TBL] [Abstract][Full Text] [Related]
20. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Banfor PN; Preusser LC; Campbell TJ; Marsh KC; Polakowski JS; Reinhart GA; Cox BF; Fryer RM Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H238-48. PubMed ID: 17982006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]